NNK

NNK is a nicotine-nitrosated derivative. NNK simultaneously stimulates Bcl2 phosphorylation exclusively at Ser70 and c-Myc at Thr58 and Ser62 through activation of both ERK1/2 and PKCα[1]. NNK induces survival and proliferation of human lung cancer cells. NNK can be used for lung cancer mice model structure[2].

Product Specifications

CAS Number

[64091-91-4]

UNSPSC

12352005

Hazard Statement

H301, H317, H351

Target

Endogenous Metabolite

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/nnk.html

Concentration

10mM

Purity

99.98

Solubility

DMSO : ≥ 62.5 mg/mL

Smiles

O=C(C1=CC=CN=C1)CCCN(C)N=O

Molecular Formula

C10H13N3O2

Molecular Weight

207.23

Precautions

H301, H317, H351

References & Citations

[1]Jin Z, et al. Tobacco-specific nitrosamine 4- (methylnitrosamino) -1- (3-pyridyl) -1-butanone promotes functional cooperation of Bcl2 and c-Myc through phosphorylation in regulating cell survival and proliferation. J Biol Chem. 2004;279 (38) :40209-40219.|[2]Castonguay A, et al. Lung tumorigenicity of NNK given orally to A/J mice: its application to chemopreventive efficacy studies. Exp Lung Res. 1991;17 (2) :485-499.|[3]Ge GZ, et al. Tobacco carcinogen NNK-induced lung cancer animal models and associated carcinogenic mechanisms. Acta Biochim Biophys Sin (Shanghai) . 2015 Jul;47 (7) :477-87. |[4]Razani-Boroujerdi S, et al. Early manifestations of NNK-induced lung cancer: role of lung immunity in tumor susceptibility. Am J Respir Cell Mol Biol. 2007 Jan;36 (1) :13-9.